A key panel of US health advisers voted in favor of lowering the age recommendation for vaccines made by Pfizer Inc. and ...

Advisers to the Centers for Disease Control and Prevention on Wednesday recommended expanding the use of vaccines to adults between 50-64 years to protect against pneumococcal disease.

Genentech, the biotech unit of Swiss major Roche, has been marketing lung cancer drugs for nearly two decades, starting with ...

Modifi Biosciences, a New Haven startup biotech that focuses on developing cancer therapies, has been acquired by ...

Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Merck & Company (MRK – Research Report), with a ...

We recently compiled a list of the 8 Most Undervalued Value Stocks To Buy According To Analysts. In this article, we are ...

Merck & Co. has acquired Modifi Biosciences, a developer of cancer therapies that was spun out of Yale University, in a deal potentially worth more than $1 billion.

Shawn Li, principal scientist at Merck & Co., known as MSD outside the Unites States and Canada, talked about the importance ...

Edward’s Syndrome Treatment MarketThe global Edward’s syndrome treatment market is set for significant growth, with a projected market value of USD 7.98 Billion by 2033, according to a newly released ...

PMV Pharmaceuticals is collaborating with MD Anderson Cancer Center (MDACC) and Memorial Sloan Kettering Cancer Center (MSK) to support an investigator-initiated Phase 1b study evaluating rezatapopt ...

Under the terms of the agreement Merck, through a subsidiary, has acquired all outstanding shares of Modifi Biosciences for $30 million upfront. Modifi Biosciences shareholders are also eligible to ...